A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.

Katerina Chatzidionysiou; Carl Turesson; Annika Teleman; Ann Knight; Elisabet Lindqvist; Per Larsson; Lars Cöster; Kristina Forslind; Ronald van Vollenhoven; Mikael Heimbürger

doi:10.1136/rmdopen-2015-000133

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.

Katerina Chatzidionysiou, Carl Turesson, Annika Teleman, Ann Knight, Elisabet Lindqvist, Per Larsson, Lars Cöster, Kristina Forslind, Ronald van Vollenhoven, Mikael Heimbürger

Research output: Contribution to journal › Article › peer-review

Abstract

Treatment with tumour necrosis factor (TNF) blockers, once started as therapy for rheumatoid arthritis (RA), is usually continued indefinitely. The aim of this trial was to assess the possibility of discontinuing treatment with adalimumab (ADA) while maintaining remission in patients with RA with established disease in stable remission on combination therapy with ADA and methotrexate (MTX).

Original language	English
Pages (from-to)	e000133
Journal	RMD Open
Volume	2
Issue number	1
DOIs	https://doi.org/10.1136/rmdopen-2015-000133
Publication status	Published - 2016

Subject classification (UKÄ)

Rheumatology and Autoimmunity

Access to Document

10.1136/rmdopen-2015-000133

http://www.ncbi.nlm.nih.gov/pubmed/26819752?dopt=Abstract

Cite this

Chatzidionysiou, K., Turesson, C., Teleman, A., Knight, A., Lindqvist, E., Larsson, P., Cöster, L., Forslind, K., van Vollenhoven, R., & Heimbürger, M. (2016). A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open, 2(1), e000133. https://doi.org/10.1136/rmdopen-2015-000133

@article{b2878c4b49eb45b59d29dcce21d61a17,

title = "A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.",

abstract = "Treatment with tumour necrosis factor (TNF) blockers, once started as therapy for rheumatoid arthritis (RA), is usually continued indefinitely. The aim of this trial was to assess the possibility of discontinuing treatment with adalimumab (ADA) while maintaining remission in patients with RA with established disease in stable remission on combination therapy with ADA and methotrexate (MTX).",

author = "Katerina Chatzidionysiou and Carl Turesson and Annika Teleman and Ann Knight and Elisabet Lindqvist and Per Larsson and Lars C{\"o}ster and Kristina Forslind and {van Vollenhoven}, Ronald and Mikael Heimb{\"u}rger",

year = "2016",

doi = "10.1136/rmdopen-2015-000133",

language = "English",

volume = "2",

pages = "e000133",

journal = "RMD Open",

issn = "2056-5933",

publisher = "BMJ Publishing Group",

number = "1",

}

Chatzidionysiou, K, Turesson, C, Teleman, A, Knight, A, Lindqvist, E, Larsson, P, Cöster, L, Forslind, K, van Vollenhoven, R & Heimbürger, M 2016, 'A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.', RMD Open, vol. 2, no. 1, pp. e000133. https://doi.org/10.1136/rmdopen-2015-000133

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. / Chatzidionysiou, Katerina; Turesson, Carl; Teleman, Annika et al.
In: RMD Open, Vol. 2, No. 1, 2016, p. e000133.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.

AU - Chatzidionysiou, Katerina

AU - Turesson, Carl

AU - Teleman, Annika

AU - Knight, Ann

AU - Lindqvist, Elisabet

AU - Larsson, Per

AU - Cöster, Lars

AU - Forslind, Kristina

AU - van Vollenhoven, Ronald

AU - Heimbürger, Mikael

PY - 2016

Y1 - 2016

N2 - Treatment with tumour necrosis factor (TNF) blockers, once started as therapy for rheumatoid arthritis (RA), is usually continued indefinitely. The aim of this trial was to assess the possibility of discontinuing treatment with adalimumab (ADA) while maintaining remission in patients with RA with established disease in stable remission on combination therapy with ADA and methotrexate (MTX).

AB - Treatment with tumour necrosis factor (TNF) blockers, once started as therapy for rheumatoid arthritis (RA), is usually continued indefinitely. The aim of this trial was to assess the possibility of discontinuing treatment with adalimumab (ADA) while maintaining remission in patients with RA with established disease in stable remission on combination therapy with ADA and methotrexate (MTX).

U2 - 10.1136/rmdopen-2015-000133

DO - 10.1136/rmdopen-2015-000133

M3 - Article

C2 - 26819752

SN - 2056-5933

VL - 2

SP - e000133

JO - RMD Open

JF - RMD Open

IS - 1

ER -

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.

Abstract

Subject classification (UKÄ)

Access to Document

Fingerprint

Cite this